Bone Metabolism Therapeutics Market To 2018 - Hyperparathyroidism Sector To Decline In The Absence Of New Product Launches And Increased Generic Erosion For Zemplar, Hectorol And Sensipar
- Key M&A activities and Licensing Agreements that took place in 2009 and 2011 in the metabolic disorders therapeutics market.
Reasons to buy
- Align your product portfolio to the markets with high growth potential. - Build effective strategies to launch their pipeline products by identifying potential geographies. - Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps. - Develop key strategic initiatives by studying the key strategies of top competitors. - Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication. - Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth. - Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious. Table of Contents 1 Table of Contents 1 Table of Contents 5 1.1 List of Tables 7 1.2 List of Figures 9 2 Introduction 11 3 Bone Metabolism Therapeutics Market to 2018 - Market Overview 12 3.1 Introduction 12 3.1.1 Revenue 12 3.1.2 Annual Cost of Treatment 13 3.1.3 Treatment Usage Patterns 14 4 Bone Metabolism Therapeutics Market to 2018 - Geographical Landscape 16 4.1 Revenue Analysis by Geography 16 4.2 The US 18 4.2.1 Revenue 18 4.2.2 Annual Cost of Treatment 19 4.2.3 Treatment Usage Patterns 20 4.3 Top Five Countries of Europe 22 4.3.1 Revenue 22 4.3.2 Annual Cost of Treatment 24 4.3.3 Treatment Usage Patterns 25 4.4 Japan 27 4.4.1 Revenue 27 4.4.2 Annual Cost of Treatment 28 4.4.3 Treatment Usage Patterns 29 5 Bone Metabolism Therapeutics Market to 2018 - Therapeutic Landscape 31 5.1 Osteoporosis Therapeutics Market 31 5.1.1 Introduction 31 5.1.2 Revenue 31 5.1.3 Annual Cost of Treatment 35
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts